India Glycols Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.0 pts less than its Breweries & Distilleries peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
India Glycols reported its Q1 FY26 (quarter ended June 30, 2025) results with standalone revenue from operations at ₹2,503.03 cr, up about 9.7% from ₹2,282.43 cr in Q1 FY25. Standalone profit after tax rose to ₹52.66 cr from ₹46.78 cr, while EPS stood at ₹17.07 vs ₹15.10. On a consolidated basis, revenue was ₹2,503.12 cr and PAT was ₹73.25 cr (vs ₹60.38 cr), boosted by an ₹18.62 cr share of profit from joint venture Clariant IGL Specialty Chemicals. EBITDA margin expanded to about 6% from ~5.5% YoY on a standalone basis, reflecting improved operating efficiency. Statutory auditors K.N. Gutgutia & Co. issued an unqualified limited review report. The Board also noted updates on the Composite Scheme of Arrangement (Demerger of Bio Pharma and Spirits & Biofuel businesses) and the approved 1:2 stock split, with record date set for August 12, 2025.
Modest top-line growth with margin expansion and a clean auditor review are positive signals for shareholders. The stock split (effective Aug 12) will improve liquidity and affordability, while the proposed demerger could unlock value over time. Near-term stock reaction likely to be driven by the steady earnings show, with limited negative triggers.